Hydrocodone Reclassification: What Pharmacists Need to Know
All drugs containing the opioid hydrocodone have been reclassified as Schedule II controlled substances, prohibiting pharmacies from recognizing refills and phoned-in prescriptions for those medications.
Under a new Drug Enforcement Administration (DEA) rule implemented today, all drugs containing the opioid hydrocodone have been reclassified as Schedule II controlled substances, prohibiting pharmacies from recognizing refills and phoned-in prescriptions for those medications.
The DEA
For valid hydrocodone prescriptions submitted prior to today’s date, pharmacies can legally allow authorized refills until April 8, 2015. However, pharmacy groups have pointed out that state laws, payer policies, and issues with pharmacy quality and safety processes may prevent pharmacies from filling those remaining refills.
“Most states have not provided clarity with respect to whether such refills will be valid under state law. Moreover, most pharmacies will not be able to process such refills due to existing quality and safety operations and processes,” the National Association of Chain Drug Stores noted in a statement submitted to a US House of Representatives panel.
Likewise, Michael H. Ghobrial, PharmD, JD, associate director of health policy for the American Pharmacists Association, said his organization has been informed that “some pharmacies may not be refilling pending fills because of software issues with prescription processing tools, confusion around conflicting state laws, and payer policies.”
“Some pharmacies may not be able to reprogram their computer systems in time to recognize, as of October 6, a C-II as refillable until April 8, 2015, and only several states have officially stated that they will allow a similar accommodation in state law authorizing refills on a federal Schedule II drug for up to 6 months,” Dr. Ghobrial told Pharmacy Today.
Relative to the confusion, a recent Pharmacy Times poll revealed that 72% of responders believe the hydrocodone rescheduling will slow down their work flow. Those results reflect the sentiments of Jay Sochoka, RPh, BSPharm, CIP, who argued in a
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Related Articles
- IMS 2025: Improving Outcomes with Bispecifics in Multiple Myeloma
September 19th 2025
- Effectively Managing Immunizations in the Long-Term Care Setting
September 18th 2025
- Creating a Culture of Quality in Fast-Melt Tablet Development
September 18th 2025